Patents by Inventor Jinsong Hao

Jinsong Hao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10968232
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 6, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Harry R. Chobanian, Shuwen He, Jinsong Hao, Barbara Pio, Yan Guo, Dong Xiao
  • Publication number: 20190367495
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Application
    Filed: December 1, 2017
    Publication date: December 5, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Harry R. Chobanian, Shuwen He, Jinsong Hao, Barbara Pio
  • Publication number: 20190337961
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Application
    Filed: December 15, 2017
    Publication date: November 7, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael Miller, Harry R. Chobanian, Shuwen He, Jinsong Hao, Barbara Pio, Yan Guo, Dong Xiao
  • Patent number: 8722882
    Abstract: The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: May 13, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Bernard R. Neustadt, Andrew Stamford, Jinsong Hao, Charles Lee Jayne, Yan Xia
  • Patent number: 8415353
    Abstract: Compounds of the Formula (I), where W represents CH or N; and Q represents —CN, —C(?NOH)NH2, —CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: April 9, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joel M. Harris, Bernard R. Neustadt, Hong Liu, Jinsong Hao, Andrew W. Stamford
  • Patent number: 8222259
    Abstract: Compounds of the Formula I wherein R1 and R2 together with the carbon atoms to which they are bonded optionally form a further heteroaromatic ring of the formula (II) as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: July 17, 2012
    Assignee: Schering Corporation
    Inventors: Joel M. Harris, Bernard R. Neustadt, Jinsong Hao, Andrew W. Stamford
  • Publication number: 20120040975
    Abstract: The present invention relates to Bridged Bicyclic Heterocycle Derivatives, compositions comprising a Bridged Bicyclic Heterocycle Derivative, and methods of using the Bridged Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a GPCR in a patient.
    Type: Application
    Filed: April 1, 2010
    Publication date: February 16, 2012
    Inventors: Santhosh Francis Neelamkavil, Bernard R. Neustadt, Andrew Stamford, Yan Xia, Joel M. Harris, Craig D. Boyle, Samuel Chackalamannil, Dipshikha Biswas, Hong Liu, Jinsong Hao, Claire M. Lankin, Unmesh Shah
  • Publication number: 20110263570
    Abstract: The present invention relates to Pyriraidine Derivatives of formula (I), compositions comprising a Pyrimidine Derivative, and methods of using the Pyrimidine Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient.
    Type: Application
    Filed: December 21, 2009
    Publication date: October 27, 2011
    Applicant: Schering Corporation
    Inventors: Bernard R. Neustadt, Andrew Stamford, Jinsong Hao, Charles Lee Jayne, Yan Xia
  • Publication number: 20110152256
    Abstract: Compounds of the Formula I wherein R1 and R2 together with the carbon atoms to which they are bonded optionally form a further heteroaromatic ring of the formula (II) as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.
    Type: Application
    Filed: March 3, 2009
    Publication date: June 23, 2011
    Inventors: Joel M. Harris, Bernard R. Neustadt, Hong Liu, Jinsong Hao, Andrew W. Stamford
  • Publication number: 20110118286
    Abstract: The present invention relates to Bicyclic Heterocycle Derivatives of Formula (I), compositions comprising a Bicyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a diabetic complication, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of a G protein-coupled receptor (GPCR) in a patient.
    Type: Application
    Filed: July 15, 2009
    Publication date: May 19, 2011
    Inventors: Santhosh Francis Neelamkavil, Craig D. Boyle, Joel M. Harris, Andre Stamford, Jinsong Hao, Bernard R. Neustadt, Samuel Chackalamannil, Yan Xia, Wiliam J. Greenlee
  • Publication number: 20110105513
    Abstract: Compounds of the Formula (I), where W represents CH or N; and Q represents —CN, —C(?NOH)NH2, —CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof. Care adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.
    Type: Application
    Filed: March 3, 2009
    Publication date: May 5, 2011
    Inventors: Joel M. Harris, Bernard R. Neustadt, Hong Liu, Jinsong Hao, Andrew W. Stamford
  • Publication number: 20110065671
    Abstract: The present invention relates to Bicyclic Heterocycle Derivatives of formula (I), compositions comprising a Bi-cyclic Heterocycle Derivative, and methods of using the Bicyclic Heterocycle Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of GPR1 19 in a patient.
    Type: Application
    Filed: May 18, 2009
    Publication date: March 17, 2011
    Inventors: Joel M. Harris, Santhosh Francis, Bernard R. Neustadt, Craig D. Boyle, Hong Liu, Jinsong Hao, Andrew Starnford, Samuel Chackalamannil, William J. Greenlee
  • Publication number: 20100190687
    Abstract: The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 (“GPR119”) in a patient.
    Type: Application
    Filed: April 17, 2008
    Publication date: July 29, 2010
    Inventors: Craig D. Boyle, Santhosh Francis Neelamkavil, Samuel Chackalamannil, Bernard R. Neustadt, Jinsong Hao, Unmesh G. Shah, Joel M. Harris, Hong Liu, Andrew W. Stamford
  • Patent number: 7709492
    Abstract: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 19, 2005
    Date of Patent: May 4, 2010
    Assignee: Schering Corporation
    Inventors: Bernard R. Neustadt, Jinsong Hao, Hong Liu, Craig D. Boyle, Samuel Chackalamannil, Unmesh G. Shah, Andrew Stamford, Joel M. Harris
  • Patent number: 7368449
    Abstract: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: May 6, 2008
    Assignee: Schering Corporation
    Inventors: Bernard R. Neustadt, Jinsong Hao, Hong Liu, Craig D. Boyle, Samuel Chackalamannil, Unmesh G. Shah, Andrew Stamford
  • Publication number: 20060067995
    Abstract: Topical and/or transdermal bioactive compound delivery system The present invention provides a topical and/or transdermal bioactive compound delivery system comprising a non-aqueous matrix, the matrix comprising a water-sensitive bioactive compound. In particular, the matrix comprises a three-dimensional polymeric network comprising at least a co-polymer, at least a cross-linking agent, and at least a non-aqueous and/or non-volatile solvent and wherein the water-sensitive bioactive compound is housed by the three-dimensional network. Even more in particular, the matrix comprises a co-polymer of N-vinylacetamide and sodium acrylate aluminium chloride; N-methyl-2-pyrrolidone; propylene glycol; glycerine; and at least a water-sensitive bioactive compound.
    Type: Application
    Filed: July 1, 2005
    Publication date: March 30, 2006
    Inventors: Wan Sia Heng, Jinsong Hao, Lai Chan, Ma Nyunt, Gil Yosipovitch, Yolande Anthony
  • Publication number: 20050239795
    Abstract: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; and Z is optionally substituted aryl or heteroaryl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: April 19, 2005
    Publication date: October 27, 2005
    Inventors: Bernard Neustadt, Jinsong Hao, Hong Liu, Craig Boyle, Samuel Chackalamannil, Unmesh Shah, Andrew Stamford, Joel Harris
  • Publication number: 20050222164
    Abstract: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 23, 2005
    Publication date: October 6, 2005
    Inventors: Bernard Neustadt, Jinsong Hao, Hong Liu, Craig Boyle, Samuel Chackalamannil, Unmesh Shah, Andrew Stamford
  • Patent number: 6897217
    Abstract: Compounds having the structural formula I or a pharmaceutically acceptable salt thereof, wherein R is R1, R2, R3, R4 and R5 are H, alkyl or alkoxyalkyl; R6 is H, alkyl, hydroxyalkyl or —CH2F; R7, R8 and R9 are H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo or —CF3; and Z is optionally substituted aryl, heteroaryl or heteroaryl-alkyl are disclosed. Also disclosed is the use of compounds of formula I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: April 21, 2004
    Date of Patent: May 24, 2005
    Assignee: Schering Corporation
    Inventors: Bernard R. Neustadt, Jinsong Hao, Hong Liu, Craig D. Boyle, Samuel Chackalamannil, Unmesh G. Shah, Andrew Stamford
  • Publication number: 20040220194
    Abstract: Compounds having the structural formula I 1
    Type: Application
    Filed: April 21, 2004
    Publication date: November 4, 2004
    Applicant: Schering Corporation
    Inventors: Bernard R. Neustadt, Jinsong Hao, Hong Liu, Craig D. Boyle, Samuel Chackalamannil, Unmesh G. Shah, Andrew Stamford